UroMems’ breakthrough technology successfully treats stress urinary incontinence in women
UroMems, based in Grenoble, France, has announced positive results from its first-ever female-only study of its UroActive smart implant for stress urinary incontinence (SUI). The device, which uses a MyoElectroMechanical system (MEMS), was implanted in women suffering from SUI and met its primary endpoints at the six-month mark.
Key Study Results:
- Successful Primary Endpoints: All six women in the study achieved primary endpoints, with the first patient approaching two years post-implant.
- No Complications: The devices operated as expected, with no need for revisions or explants.
- Improved Quality of Life: Secondary outcomes, including leak rate values and patient quality of life, showed “phenomenal” improvement.
UroMems’ CEO, Hamid Lamraoui, emphasized the significance of this milestone, highlighting that the implant has provided women suffering from SUI with a new, effective solution. The company has successfully extended its groundbreaking technology to both men and women, with 12 patients now treated.
This study marks a critical advancement for SUI treatment and holds promise for wider adoption across Europe and the U.S. as UroMems progresses with its clinical trials following a $47 million funding raise in June 2024.
Follow MEDWIRE.AI for the latest on innovations in medical devices and treatments.
